ID   AGAL_HUMAN              Reviewed;         429 AA.
AC   P06280; Q6LER7;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   10-MAY-2017, entry version 199.
DE   RecName: Full=Alpha-galactosidase A;
DE            EC=3.2.1.22 {ECO:0000269|PubMed:26415523, ECO:0000269|PubMed:27211852};
DE   AltName: Full=Alpha-D-galactosidase A;
DE   AltName: Full=Alpha-D-galactoside galactohydrolase;
DE   AltName: Full=Melibiase;
DE   AltName: INN=Agalsidase;
DE   Flags: Precursor;
GN   Name=GLA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fibroblast;
RX   PubMed=3036505; DOI=10.1111/j.1432-1033.1987.tb11438.x;
RA   Tsuji S., Martin B.M., Kaslow D.C., Migeon B.R., Choudary P.V.,
RA   Stubblefield B.K., Mayor J.A., Murray G.J., Barranger J.A.,
RA   Ginns E.I.;
RT   "Signal sequence and DNA-mediated expression of human lysosomal alpha-
RT   galactosidase A.";
RL   Eur. J. Biochem. 165:275-280(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Lymphoblast;
RX   PubMed=2542896; DOI=10.1093/nar/17.8.3301;
RA   Kornreich R., Desnick R.J., Bishop D.F.;
RT   "Nucleotide sequence of the human alpha-galactosidase A gene.";
RL   Nucleic Acids Res. 17:3301-3302(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7626884; DOI=10.1007/BF00364796;
RA   Oeltjen J.C., Liu X., Lu J., Allen R.C., Muzny D.M., Belmont J.W.,
RA   Gibbs R.A.;
RT   "Sixty-nine kilobases of contiguous human genomic sequence containing
RT   the alpha-galactosidase A and Bruton's tyrosine kinase loci.";
RL   Mamm. Genome 6:334-338(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 27-429, AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Lung;
RX   PubMed=3014515; DOI=10.1073/pnas.83.13.4859;
RA   Bishop D.F., Calhoun D.H., Bernstein H.S., Hantzopoulos P., Quinn M.,
RA   Desnick R.J.;
RT   "Human alpha-galactosidase A: nucleotide sequence of a cDNA clone
RT   encoding the mature enzyme.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:4859-4863(1986).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-64.
RX   PubMed=2892762; DOI=10.1016/0378-1119(87)90374-X;
RA   Quinn M., Hantzopoulos P., Fidanza V., Calhoun D.H.;
RT   "A genomic clone containing the promoter for the gene encoding the
RT   human lysosomal enzyme, alpha-galactosidase A.";
RL   Gene 58:177-188(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-64.
RX   PubMed=2836863; DOI=10.1073/pnas.85.11.3903;
RA   Bishop D.F., Kornreich R., Desnick R.J.;
RT   "Structural organization of the human alpha-galactosidase A gene:
RT   further evidence for the absence of a 3' untranslated region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3903-3907(1988).
RN   [9]
RP   RNA EDITING OF POSITION 396.
RX   PubMed=7503918; DOI=10.1093/nar/23.14.2636;
RA   Novo F.J., Kruszewski A., McDermot K.D., Goldspink G., Gorecki D.C.;
RT   "Editing of human alpha-galactosidase RNA resulting in a pyrimidine to
RT   purine conversion.";
RL   Nucleic Acids Res. 23:2636-2640(1995).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-215.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (3.45 ANGSTROMS) OF 32-422 IN COMPLEX WITH
RP   PRODUCT, HOMODIMERIZATION, AND GLYCOSYLATION AT ASN-139; ASN-192 AND
RP   ASN-215.
RX   PubMed=15003450; DOI=10.1016/j.jmb.2004.01.035;
RA   Garman S.C., Garboczi D.N.;
RT   "The molecular defect leading to Fabry disease: structure of human
RT   alpha-galactosidase.";
RL   J. Mol. Biol. 337:319-335(2004).
RN   [14]
RP   REVIEW ON FD VARIANTS.
RX   PubMed=7911050; DOI=10.1002/humu.1380030204;
RA   Eng C.M., Desnick R.J.;
RT   "Molecular basis of Fabry disease: mutations and polymorphisms in the
RT   human alpha-galactosidase A gene.";
RL   Hum. Mutat. 3:103-111(1994).
RN   [15]
RP   INVOLVEMENT IN FD, AND VARIANT FD SER-40.
RX   PubMed=2152885; DOI=10.1016/0014-5793(90)80046-L;
RA   Koide T., Ishiura M., Iwai K., Inoue M., Kaneda Y., Okada Y.,
RA   Uchida T.;
RT   "A case of Fabry's disease in a patient with no alpha-galactosidase A
RT   activity caused by a single amino acid substitution of Pro-40 by
RT   Ser.";
RL   FEBS Lett. 259:353-356(1990).
RN   [16]
RP   VARIANT FD VAL-296.
RX   PubMed=1846223; DOI=10.1056/NEJM199102073240607;
RA   von Scheidt W., Eng C.M., Fitzmaurice T.F., Erdmann E., Hubner G.,
RA   Olsen E.G.J., Christomanou H., Kandolf R., Bishop D.F., Desnick R.J.;
RT   "An atypical variant of Fabry's disease with manifestations confined
RT   to the myocardium.";
RL   N. Engl. J. Med. 324:395-399(1991).
RN   [17]
RP   VARIANT FD GLN-301.
RX   PubMed=2171331;
RA   Sakuraba H., Oshima A., Fukuhara Y., Shimmoto M., Nagao Y.,
RA   Bishop D.F., Desnick R.J., Suzuki Y.;
RT   "Identification of point mutations in the alpha-galactosidase A gene
RT   in classical and atypical hemizygotes with Fabry disease.";
RL   Am. J. Hum. Genet. 47:784-789(1990).
RN   [18]
RP   VARIANT FD TRP-356.
RX   PubMed=2539398; DOI=10.1172/JCI114027;
RA   Bernstein H.S., Bishop D.F., Astrin K.H., Kornreich R., Eng C.M.,
RA   Sakuraba H., Desnick R.J.;
RT   "Fabry disease: six gene rearrangements and an exonic point mutation
RT   in the alpha-galactosidase gene.";
RL   J. Clin. Invest. 83:1390-1399(1989).
RN   [19]
RP   VARIANTS FD GLN-66; CYS-112; GLU-279; GLN-301 AND ARG-328.
RX   PubMed=1315715; DOI=10.1007/BF00207037;
RA   Ishii S., Sakuraba H., Suzuki Y.;
RT   "Point mutations in the upstream region of the alpha-galactosidase A
RT   gene exon 6 in an atypical variant of Fabry disease.";
RL   Hum. Genet. 89:29-32(1992).
RN   [20]
RP   VARIANTS FD SER-34; GLY-56; ARG-162; GLN-227; VAL-264; VAL-266;
RP   PHE-297; TYR-313; ALA-328 AND ARG-404 DEL.
RX   PubMed=7504405;
RA   Eng C.M., Resnick-Silverman L.A., Niehaus D.J., Astrin K.H.,
RA   Desnick R.J.;
RT   "Nature and frequency of mutations in the alpha-galactosidase A gene
RT   that cause Fabry disease.";
RL   Am. J. Hum. Genet. 53:1186-1197(1993).
RN   [21]
RP   VARIANTS FD SER-34; SER-215; ALA-269; LYS-327 AND ARG-361.
RX   PubMed=8395937; DOI=10.1093/hmg/2.7.1051;
RA   Davies J.P., Winchester B.G., Malcolm S.;
RT   "Mutation analysis in patients with the typical form of Anderson-Fabry
RT   disease.";
RL   Hum. Mol. Genet. 2:1051-1053(1993).
RN   [22]
RP   VARIANTS FD ARG-35; LEU-49; VAL-165 AND GLU-316.
RX   PubMed=8069316; DOI=10.1093/hmg/3.4.667;
RA   Davies J.P., Christomanou H., Winchester B.G., Malcolm S.;
RT   "Detection of 8 new mutations in the alpha-galactosidase A gene in
RT   Fabry disease.";
RL   Hum. Mol. Genet. 3:667-669(1994).
RN   [23]
RP   VARIANTS FD.
RX   PubMed=7531540; DOI=10.1093/hmg/3.10.1795;
RA   Eng C.M., Niehaus D.J., Enriquez A.L., Burgert T.S., Ludman M.D.,
RA   Desnick R.J.;
RT   "Fabry disease: twenty-three mutations including sense and antisense
RT   CpG alterations and identification of a deletional hot-spot in the
RT   alpha-galactosidase A gene.";
RL   Hum. Mol. Genet. 3:1795-1799(1994).
RN   [24]
RP   VARIANTS FD GLN-66; CYS-112; VAL-156; VAL-166; ALA-260; GLU-279;
RP   ILE-296; GLN-301; LYS-320; ARG-328 AND SER-373.
RX   PubMed=7575533; DOI=10.1006/bbrc.1995.2416;
RA   Okumiya T., Ishii S., Takenaka T., Kase R., Kamei S., Sakuraba H.,
RA   Suzuki Y.;
RT   "Galactose stabilizes various missense mutants of alpha-galactosidase
RT   in Fabry disease.";
RL   Biochem. Biophys. Res. Commun. 214:1219-1224(1995).
RN   [25]
RP   VARIANTS FD TYR-142; VAL-156 AND VAL-166.
RX   PubMed=7759078; DOI=10.1007/BF00223869;
RA   Okumiya T., Ishii S., Kase R., Kamei S., Sakuraba H., Suzuki Y.;
RT   "Alpha-galactosidase gene mutations in Fabry disease: heterogeneous
RT   expressions of mutant enzyme proteins.";
RL   Hum. Genet. 95:557-561(1995).
RN   [26]
RP   VARIANTS FD PRO-32; SER-34; ASP-85; THR-156 AND GLN-301.
RX   PubMed=7599642; DOI=10.1002/humu.1380050316;
RA   Madsen K.M., Hasholt L., Soerensen S.A., Lagerstroem Fermer M.,
RA   Dahl N.;
RT   "Two novel mutations (L32P) and (G85N) among five different missense
RT   mutations in six Danish families with Fabry's disease.";
RL   Hum. Mutat. 5:277-278(1995).
RN   [27]
RP   VARIANTS FD PRO-20 AND ILE-296.
RX   PubMed=7596372; DOI=10.1056/NEJM199508033330504;
RA   Nakao S., Takenaka T., Maeda M., Kodama C., Tanaka A., Tahara M.,
RA   Yoshida A., Kuriyama M., Hayashibe H., Sakuraba H., Tanaka H.;
RT   "An atypical variant of Fabry's disease in men with left ventricular
RT   hypertrophy.";
RL   N. Engl. J. Med. 333:288-293(1995).
RN   [28]
RP   VARIANT FD GLN-301.
RX   PubMed=8738659;
RA   Sawada K., Mizoguchi K., Hishida A., Kaneko E., Koide Y.,
RA   Nishimura K., Kimura M.;
RT   "Point mutation in the alpha-galactosidase A gene of atypical Fabry
RT   disease with only nephropathy.";
RL   Clin. Nephrol. 45:289-294(1996).
RN   [29]
RP   VARIANTS FD VAL-42; SER-49; TYR-56; HIS-92; GLY-93; THR-205; CYS-236;
RP   GLY-287; HIS-298 AND ARG-340.
RX   PubMed=8875188;
RA   Davies J.P., Eng C.M., Hill J.A., Malcolm S., MacDermot K.,
RA   Winchester B.G., Desnick R.J.;
RT   "Fabry disease: fourteen alpha-galactosidase A mutations in unrelated
RT   families from the United Kingdom and other European countries.";
RL   Eur. J. Hum. Genet. 4:219-224(1996).
RN   [30]
RP   VARIANT FD PHE-383 DEL.
RX   PubMed=8834244; DOI=10.1007/BF02267068;
RA   Cariolou M.A., Christodoulides M., Manoli P., Kokkofitou A.,
RA   Tsambaos D.;
RT   "Novel trinucleotide deletion in Fabry's disease.";
RL   Hum. Genet. 97:468-470(1996).
RN   [31]
RP   VARIANTS FD ARG-52; CYS-162; ARG-265 AND 316-VAL--ASP-322 DEL.
RX   PubMed=8931708; DOI=10.1007/s004390050292;
RA   Germain D.P., Biasotto M., Tosi M., Meo T., Kahn A., Poenaru L.;
RT   "Fluorescence-assisted mismatch analysis (FAMA) for exhaustive
RT   screening of the alpha-galactosidase A gene and detection of carriers
RT   in Fabry disease.";
RL   Hum. Genet. 98:719-726(1996).
RN   [32]
RP   VARIANTS FD ARG-52; GLU-128; THR-205; THR-284; LYS-298 AND GLU-358
RP   DEL.
RX   PubMed=8807334;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:1<38::AID-HUMU5>3.0.CO;2-L;
RA   Blanch L.C., Meaney C., Morris C.P.;
RT   "A sensitive mutation screening strategy for Fabry disease: detection
RT   of nine mutations in the alpha-galactosidase A gene.";
RL   Hum. Mutat. 8:38-43(1996).
RN   [33]
RP   VARIANT FD ASN-231.
RX   PubMed=8863162; DOI=10.1136/jmg.33.8.682;
RA   Redonnet-Vernhet I., Ploos van Amstel J.K., Jansen R.P.M.,
RA   Wevers R.A., Salvayre R., Levade T.;
RT   "Uneven X inactivation in a female monozygotic twin pair with Fabry
RT   disease and discordant expression of a novel mutation in the alpha-
RT   galactosidase A gene.";
RL   J. Med. Genet. 33:682-688(1996).
RN   [34]
RP   VARIANTS FD PRO-20; SER-40; GLN-66; VAL-72; CYS-112; TYR-142; VAL-156;
RP   VAL-166; ASN-242; ALA-260; ASP-261; GLU-279; ILE-296; GLN-301;
RP   LYS-320; ARG-328; GLU-358 DEL AND SER-373.
RX   PubMed=9105656; DOI=10.1016/S0387-7604(96)00486-X;
RA   Takata T., Okumiya T., Hayashibe H., Shimmoto M., Kase R., Itoh K.,
RA   Utsumi K., Kamei S., Sakuraba H.;
RT   "Screening and detection of gene mutations in Japanese patients with
RT   Fabry disease by non-radioactive single-stranded conformation
RT   polymorphism analysis.";
RL   Brain Dev. 19:111-116(1997).
RN   [35]
RP   VARIANTS FD VAL-31; 45-ARG-SER-46; ARG-46; CYS-86; PRO-89; THR-91;
RP   TYR-92; TYR-94; VAL-97; THR-100; LEU-113; SER-134; ARG-138; THR-143;
RP   ARG-148; VAL-163; VAL-170; TYR-202; 205-PRO--TYR-207 DEL; ASP-216;
RP   SER-263; CYS-287; SER-298 AND ARG-404 DEL.
RX   PubMed=9100224;
RA   Eng C.M., Ashley G.A., Burgert T.S., Enriquez A.L., D'Souza M.,
RA   Desnick R.J.;
RT   "Fabry disease: thirty-five mutations in the alpha-galactosidase A
RT   gene in patients with classic and variant phenotypes.";
RL   Mol. Med. 3:174-182(1997).
RN   [36]
RP   VARIANT FD THR-65.
RX   PubMed=9554750;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<328::AID-HUMU11>3.0.CO;2-N;
RA   Chen C.-H., Shyu P.-W., Wu S.-J., Sheu S.-S., Desnick R.J.,
RA   Hsiao K.-J.;
RT   "Identification of a novel point mutation (S65T) in alpha-
RT   galactosidase A gene in Chinese patients with Fabry disease.";
RL   Hum. Mutat. 11:328-330(1998).
RN   [37]
RP   VARIANT FD LYS-358.
RX   PubMed=9452068;
RA   Miyazaki T., Kajita M., Ohmori S., Mizutani N., Niwa T., Murata Y.,
RA   Seo H.;
RT   "A novel mutation (E358K) in the alpha-galactosidase A gene detected
RT   in a Japanese family with Fabry disease.";
RL   Hum. Mutat. Suppl. 1:S139-S140(1998).
RN   [38]
RP   VARIANT FD VAL-72.
RX   PubMed=9452090;
RA   Okumiya T., Kawamura O., Itoh K., Kase R., Ishii S., Kamei S.,
RA   Sakuraba H.;
RT   "Novel missense mutation (M72V) of alpha-galactosidase gene and its
RT   expression product in an atypical Fabry hemizygote.";
RL   Hum. Mutat. Suppl. 1:S213-S216(1998).
RN   [39]
RP   VARIANTS FD SER-40; SER-215; ASP-224; TYR-313 AND TRP-THR-SER-247 INS.
RX   PubMed=9452111;
RA   Guffon N., Froissart R., Chevalier-Porst F., Maire I.;
RT   "Mutation analysis in 11 French patients with Fabry disease.";
RL   Hum. Mutat. Suppl. 1:S288-S290(1998).
RN   [40]
RP   VARIANTS FD TRP-202; GLY-223; ASP-224; GLN-301 AND LYS-327.
RX   PubMed=10208848; DOI=10.1006/bbrc.1999.0310;
RA   Germain D.P., Poenaru L.;
RT   "Fabry disease: identification of novel alpha-galactosidase A
RT   mutations and molecular carrier detection by use of fluorescent
RT   chemical cleavage of mismatches.";
RL   Biochem. Biophys. Res. Commun. 257:708-713(1999).
RN   [41]
RP   VARIANT FD LYS-341.
RX   PubMed=10090526; DOI=10.1016/S0009-8981(98)00133-8;
RA   Beyer E.M., Karpova E.A., Udalova O.V., Ploos van Amstel J.K.,
RA   van Diggelen O.P., Tsvetkova I.V.;
RT   "The multiple cases of Fabry disease in a Russian family caused by an
RT   E341K amino acid substitution in the alpha-galactosidase A.";
RL   Clin. Chim. Acta 280:81-89(1999).
RN   [42]
RP   CHARACTERIZATION OF VARIANTS FD GLU-279 AND GLN-301.
RX   PubMed=10838196; DOI=10.1016/S0925-4439(00)00024-7;
RA   Kase R., Bierfreund U., Klein A., Kolter T., Utsumi K., Itoh K.,
RA   Sandhoff K., Sakuraba H.;
RT   "Characterization of two alpha-galactosidase mutants (Q279E and R301Q)
RT   found in an atypical variant of Fabry disease.";
RL   Biochim. Biophys. Acta 1501:227-235(2000).
RN   [43]
RP   VARIANTS FD VAL-42; CYS-112; ARG-142; ARG-148; VAL-165; ASP-183;
RP   SER-215; CYS-235; LEU-236; HIS-244; LEU-259; ILE-267; PHE-289;
RP   GLU-321; GLU-358 DEL AND TYR-378.
RX   PubMed=10666480;
RA   Topaloglu A.K., Ashley G.A., Tong B., Shabbeer J., Astrin K.H.,
RA   Eng C.M., Desnick R.J.;
RT   "Twenty novel mutations in the alpha-galactosidase A gene causing
RT   Fabry disease.";
RL   Mol. Med. 5:806-811(1999).
RN   [44]
RP   VARIANT FD ASN-266.
RX   PubMed=11076046; DOI=10.1034/j.1399-0004.2000.580311.x;
RA   Lee J.-K., Kim G.-H., Kim J.-S., Kim K.-K., Lee M.-C., Yoo H.-W.;
RT   "Identification of four novel mutations in five unrelated Korean
RT   families with Fabry disease.";
RL   Clin. Genet. 58:228-233(2000).
RN   [45]
RP   VARIANTS FD LEU-40; SER-95; CYS-112; HIS-112; ASN-148; ARG-172;
RP   VAL-187; SER-224; ARG-226; GLN-227; THR-230; HIS-266; GLN-301 AND
RP   TYR-320.
RX   PubMed=10916280;
RA   Ashton-Prolla P., Tong B., Shabbeer J., Astrin K.H., Eng C.M.,
RA   Desnick R.J.;
RT   "Fabry disease: twenty-two novel mutations in the alpha-galactosidase
RT   A gene and genotype/phenotype correlations in severely and mildly
RT   affected hemizygotes and heterozygotes.";
RL   J. Invest. Med. 48:227-235(2000).
RN   [46]
RP   VARIANT FD ASP-373.
RX   PubMed=11295840; DOI=10.1002/humu.41;
RA   Germain D.P., Salard D., Fellmann F., Azibi K., Caillaud C.,
RA   Bernard M.-C., Poenaru L.;
RT   "Identification of a novel de novo mutation (G373D) in the alpha-
RT   galactosidase A gene (GLA) in a patient affected with Fabry disease.";
RL   Hum. Mutat. 17:353-353(2001).
RN   [47]
RP   VARIANTS FD TYR-46; GLY-47; PRO-49; SER-94; SER-95; CYS-112; SER-113;
RP   THR-143; SER-215; ARG-258; ARG-259; ILE-267; HIS-279; HIS-280;
RP   HIS-298; TYR-313; HIS-363; ASP-377; ALA-409 AND THR-409.
RX   PubMed=11668641; DOI=10.1002/humu.1219;
RA   Blaydon D., Hill J.A., Winchester B.G.;
RT   "Fabry disease: 20 novel GLA mutations in 35 families.";
RL   Hum. Mutat. 18:459-459(2001).
RN   [48]
RP   VARIANT FD PRO-143.
RX   PubMed=11889412; DOI=10.1097/00005792-200203000-00003;
RA   Branton M.H., Schiffmann R., Sabnis S.G., Murray G.J., Quirk J.M.,
RA   Altarescu G., Goldfarb L., Brady R.O., Balow J.E., Austin H.A. III,
RA   Kopp J.B.;
RT   "Natural history of Fabry renal disease: influence of alpha-
RT   galactosidase A activity and genetic mutations on clinical course.";
RL   Medicine (Baltimore) 81:122-138(2002).
RN   [49]
RP   VARIANT FD ALA-410.
RX   PubMed=12694230; DOI=10.1034/j.1399-0004.2003.00050.x;
RA   Yang C.-C., Lai L.-W., Whitehair O., Hwu W.-L., Chiang S.-C.,
RA   Lien Y.-H.H.;
RT   "Two novel mutations in the alpha-galactosidase A gene in Chinese
RT   patients with Fabry disease.";
RL   Clin. Genet. 63:205-209(2003).
RN   [50]
RP   CHARACTERIZATION OF VARIANT FD THR-65.
RX   PubMed=12786754; DOI=10.1034/j.1399-0004.2003.00077.x;
RA   Lai L.-W., Whitehair O., Wu M.-J., O'Meara M., Lien Y.-H.H.;
RT   "Analysis of splice-site mutations of the alpha-galactosidase A gene
RT   in Fabry disease.";
RL   Clin. Genet. 63:476-482(2003).
RN   [51]
RP   VARIANT FD SER-272.
RX   PubMed=15162124; DOI=10.1038/sj.ejhg.5201184;
RA   Verovnik F., Benko D., Vujkovac B., Linthorst G.E.;
RT   "Remarkable variability in renal disease in a large Slovenian family
RT   with Fabry disease.";
RL   Eur. J. Hum. Genet. 12:678-681(2004).
RN   [52]
RP   VARIANTS FD VAL-31; LEU-42; ARG-43; ASN-93; CYS-112; HIS-112; SER-112;
RP   SER-134; VAL-135; ASP-171; PHE-201; SER-215; GLU-234; ASP-261;
RP   TYR-264; VAL-264; GLY-276; PRO-285; PHE-300; ALA-328; VAL-328;
RP   LYS-338; ALA-358; GLU-358 DEL; ARG-404 DEL AND SER-414.
RX   PubMed=15712228; DOI=10.1002/humu.20144;
RA   Shabbeer J., Robinson M., Desnick R.J.;
RT   "Detection of alpha-galactosidase a mutations causing Fabry disease by
RT   denaturing high performance liquid chromatography.";
RL   Hum. Mutat. 25:299-305(2005).
RN   [53]
RP   VARIANT FD THR-143.
RX   PubMed=16533976; DOI=10.1001/archneur.63.3.453;
RA   Nance C.S., Klein C.J., Banikazemi M., Dikman S.H., Phelps R.G.,
RA   McArthur J.C., Rodriguez M., Desnick R.J.;
RT   "Later-onset Fabry disease: an adult variant presenting with the
RT   cramp-fasciculation syndrome.";
RL   Arch. Neurol. 63:453-457(2006).
RN   [54]
RP   VARIANTS FD 12-CYS--LEU-14 DEL; PRO-46; GLN-66; ASN-93; VAL-120;
RP   THR-219; GLN-356 AND CYS-360, AND CHARACTERIZATION OF VARIANTS FD
RP   12-CYS--LEU-14 DEL; PRO-46; GLN-66; ASN-93; VAL-120; THR-219; GLN-356
RP   AND CYS-360.
RX   PubMed=19621417; DOI=10.1002/humu.21074;
RA   Hwu W.L., Chien Y.H., Lee N.C., Chiang S.C., Dobrovolny R.,
RA   Huang A.C., Yeh H.Y., Chao M.C., Lin S.J., Kitagawa T., Desnick R.J.,
RA   Hsu L.W.;
RT   "Newborn screening for Fabry disease in Taiwan reveals a high
RT   incidence of the later-onset GLA mutation c.936+919G>A
RT   (IVS4+919G>A).";
RL   Hum. Mutat. 30:1397-1405(2009).
RN   [55]
RP   CHARACTERIZATION OF VARIANTS FD ASP-20; PRO-20; PRO-21; GLY-33;
RP   GLU-35; TRP-36; SER-40; THR-42; PRO-45; ASP-48; TYR-56; LEU-60;
RP   PHE-64; ASP-80; HIS-86; ASN-91; THR-91; SER-94; TYR-94; ILE-113;
RP   THR-121; LEU-164; GLY-164; GLN-167; PHE-180; VAL-187; SER-196;
RP   THR-198; TYR-202; ARG-204; ARG-213; LEU-214; MET-219; PRO-227;
RP   SER-228; VAL-242; PHE-243; PRO-247; LYS-249; THR-253; ALA-254;
RP   ARG-259; ARG-262; GLY-269; GLY-276; VAL-309; ASN-315; ALA-316;
RP   SER-317; TYR-320; ARG-323; ARG-327; LEU-327; ARG-328; ARG-330;
RP   PRO-342; GLY-352; PRO-356; LYS-358; SER-360; ALA-375; SER-392; SER-399
RP   AND ARG-404 DEL, CHARACTERIZATION OF VARIANTS PRO-3; VAL-3; GLY-71;
RP   THR-154; VAL-289 AND ASN-313, CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=26415523; DOI=10.1002/humu.22910;
RA   Lukas J., Scalia S., Eichler S., Pockrandt A.M., Dehn N., Cozma C.,
RA   Giese A.K., Rolfs A.;
RT   "Functional and clinical consequences of novel alpha-galactosidase A
RT   mutations in Fabry disease.";
RL   Hum. Mutat. 37:43-51(2016).
RN   [56]
RP   VARIANT FD ARG-47, CHARACTERIZATION OF VARIANTS FD ARG-47 AND GLY-47,
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=27211852; DOI=10.1080/00207454.2016.1191483;
RA   Ge W., Wei B., Zhu H., Miao Z., Zhang W., Leng C., Li J., Zhang D.,
RA   Sun M., Xu X.;
RT   "A novel mutation of alpha-galactosidase A gene causes Fabry disease
RT   mimicking primary erythromelalgia in a Chinese family.";
RL   Int. J. Neurosci. 2016:1-6(2016).
RN   [57]
RP   VARIANT FD THR-143.
RX   PubMed=27142856; DOI=10.1186/s13023-016-0441-z;
RA   Lenders M., Weidemann F., Kurschat C., Canaan-Kuehl S., Duning T.,
RA   Stypmann J., Schmitz B., Reiermann S., Kraemer J., Blaschke D.,
RA   Wanner C., Brand S.M., Brand E.;
RT   "Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.";
RL   Orphanet J. Rare Dis. 11:54-54(2016).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of terminal, non-reducing alpha-D-
CC       galactose residues in alpha-D-galactosides, including galactose
CC       oligosaccharides, galactomannans and galactolipids.
CC       {ECO:0000269|PubMed:26415523, ECO:0000269|PubMed:27211852}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:15003450}.
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- RNA EDITING: Modified_positions=396 {ECO:0000269|PubMed:7503918};
CC       Note=Partially edited.;
CC   -!- DISEASE: Fabry disease (FD) [MIM:301500]: Rare X-linked
CC       sphingolipidosis disease where glycolipid accumulates in many
CC       tissues. The disease consists of an inborn error of
CC       glycosphingolipid catabolism. FD patients show systemic
CC       accumulation of globotriaosylceramide (Gb3) and related
CC       glycosphingolipids in the plasma and cellular lysosomes throughout
CC       the body. Clinical recognition in males results from
CC       characteristic skin lesions (angiokeratomas) over the lower trunk.
CC       Patients may show ocular deposits, febrile episodes, and burning
CC       pain in the extremities. Death results from renal failure, cardiac
CC       or cerebral complications of hypertension or other vascular
CC       disease. Heterozygous females may exhibit the disorder in an
CC       attenuated form, they are more likely to show corneal opacities.
CC       {ECO:0000269|PubMed:10090526, ECO:0000269|PubMed:10208848,
CC       ECO:0000269|PubMed:10666480, ECO:0000269|PubMed:10838196,
CC       ECO:0000269|PubMed:10916280, ECO:0000269|PubMed:11076046,
CC       ECO:0000269|PubMed:11295840, ECO:0000269|PubMed:11668641,
CC       ECO:0000269|PubMed:11889412, ECO:0000269|PubMed:12694230,
CC       ECO:0000269|PubMed:12786754, ECO:0000269|PubMed:1315715,
CC       ECO:0000269|PubMed:15162124, ECO:0000269|PubMed:15712228,
CC       ECO:0000269|PubMed:16533976, ECO:0000269|PubMed:1846223,
CC       ECO:0000269|PubMed:19621417, ECO:0000269|PubMed:2152885,
CC       ECO:0000269|PubMed:2171331, ECO:0000269|PubMed:2539398,
CC       ECO:0000269|PubMed:26415523, ECO:0000269|PubMed:27142856,
CC       ECO:0000269|PubMed:27211852, ECO:0000269|PubMed:7504405,
CC       ECO:0000269|PubMed:7531540, ECO:0000269|PubMed:7575533,
CC       ECO:0000269|PubMed:7596372, ECO:0000269|PubMed:7599642,
CC       ECO:0000269|PubMed:7759078, ECO:0000269|PubMed:8069316,
CC       ECO:0000269|PubMed:8395937, ECO:0000269|PubMed:8738659,
CC       ECO:0000269|PubMed:8807334, ECO:0000269|PubMed:8834244,
CC       ECO:0000269|PubMed:8863162, ECO:0000269|PubMed:8875188,
CC       ECO:0000269|PubMed:8931708, ECO:0000269|PubMed:9100224,
CC       ECO:0000269|PubMed:9105656, ECO:0000269|PubMed:9452068,
CC       ECO:0000269|PubMed:9452090, ECO:0000269|PubMed:9452111,
CC       ECO:0000269|PubMed:9554750}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- PHARMACEUTICAL: Available under the names Replagal (from Shire)
CC       and Fabrazyme (from Genzyme). Used as a long-term enzyme
CC       replacement therapy in patients with a confirmed diagnosis of
CC       Fabry disease. The differences between Replagal (also known as
CC       agalsidase alpha) and Fabrazyme (also known as agalsidase beta)
CC       lies in the glycosylation patterns. Agalsidase beta is produced in
CC       the hamster CHO cell line while agalsidase alpha is produced in
CC       human cell lines.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 27 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X05790; CAA29232.1; -; mRNA.
DR   EMBL; X14448; CAA32617.1; -; Genomic_DNA.
DR   EMBL; U78027; AAB64203.1; -; Genomic_DNA.
DR   EMBL; AL035422; CAB55878.1; -; Genomic_DNA.
DR   EMBL; BC002689; AAH02689.1; -; mRNA.
DR   EMBL; M13571; AAA51676.1; -; Genomic_DNA.
DR   EMBL; D00039; BAA34059.1; -; mRNA.
DR   EMBL; M18242; AAA52514.1; -; Genomic_DNA.
DR   EMBL; X16889; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M20317; AAA52559.1; ALT_SEQ; Genomic_DNA.
DR   CCDS; CCDS14484.1; -.
DR   PIR; S04081; GBHUA.
DR   RefSeq; NP_000160.1; NM_000169.2.
DR   UniGene; Hs.69089; -.
DR   PDB; 1R46; X-ray; 3.25 A; A/B=32-429.
DR   PDB; 1R47; X-ray; 3.45 A; A/B=32-429.
DR   PDB; 3GXN; X-ray; 3.01 A; A/B=32-429.
DR   PDB; 3GXP; X-ray; 2.20 A; A/B=32-429.
DR   PDB; 3GXT; X-ray; 2.70 A; A/B=32-429.
DR   PDB; 3HG2; X-ray; 2.30 A; A/B=32-429.
DR   PDB; 3HG3; X-ray; 1.90 A; A/B=32-429.
DR   PDB; 3HG4; X-ray; 2.30 A; A/B=32-429.
DR   PDB; 3HG5; X-ray; 2.30 A; A/B=32-429.
DR   PDB; 3LX9; X-ray; 2.04 A; A/B=32-429.
DR   PDB; 3LXA; X-ray; 3.04 A; A/B=32-429.
DR   PDB; 3LXB; X-ray; 2.85 A; A/B=32-429.
DR   PDB; 3LXC; X-ray; 2.35 A; A/B=32-429.
DR   PDB; 3S5Y; X-ray; 2.10 A; A/B=32-429.
DR   PDB; 3S5Z; X-ray; 2.00 A; A/B=32-429.
DR   PDB; 3TV8; X-ray; 2.64 A; A/B=32-429.
DR   PDB; 4NXS; X-ray; 2.55 A; A/B=32-429.
DR   PDBsum; 1R46; -.
DR   PDBsum; 1R47; -.
DR   PDBsum; 3GXN; -.
DR   PDBsum; 3GXP; -.
DR   PDBsum; 3GXT; -.
DR   PDBsum; 3HG2; -.
DR   PDBsum; 3HG3; -.
DR   PDBsum; 3HG4; -.
DR   PDBsum; 3HG5; -.
DR   PDBsum; 3LX9; -.
DR   PDBsum; 3LXA; -.
DR   PDBsum; 3LXB; -.
DR   PDBsum; 3LXC; -.
DR   PDBsum; 3S5Y; -.
DR   PDBsum; 3S5Z; -.
DR   PDBsum; 3TV8; -.
DR   PDBsum; 4NXS; -.
DR   ProteinModelPortal; P06280; -.
DR   SMR; P06280; -.
DR   BioGrid; 108981; 14.
DR   IntAct; P06280; 6.
DR   STRING; 9606.ENSP00000218516; -.
DR   BindingDB; P06280; -.
DR   ChEMBL; CHEMBL2524; -.
DR   DrugBank; DB05018; Migalastat.
DR   SwissLipids; SLP:000001380; -.
DR   Allergome; 9621; Hom s alpha-Galactosidase.
DR   CAZy; GH27; Glycoside Hydrolase Family 27.
DR   iPTMnet; P06280; -.
DR   PhosphoSitePlus; P06280; -.
DR   BioMuta; GLA; -.
DR   EPD; P06280; -.
DR   PaxDb; P06280; -.
DR   PeptideAtlas; P06280; -.
DR   PRIDE; P06280; -.
DR   DNASU; 2717; -.
DR   Ensembl; ENST00000218516; ENSP00000218516; ENSG00000102393.
DR   GeneID; 2717; -.
DR   KEGG; hsa:2717; -.
DR   CTD; 2717; -.
DR   DisGeNET; 2717; -.
DR   GeneCards; GLA; -.
DR   GeneReviews; GLA; -.
DR   HGNC; HGNC:4296; GLA.
DR   HPA; HPA000237; -.
DR   HPA; HPA000966; -.
DR   MalaCards; GLA; -.
DR   MIM; 300644; gene.
DR   MIM; 301500; phenotype.
DR   neXtProt; NX_P06280; -.
DR   OpenTargets; ENSG00000102393; -.
DR   Orphanet; 324; Fabry disease.
DR   PharmGKB; PA28707; -.
DR   eggNOG; KOG2366; Eukaryota.
DR   eggNOG; ENOG410XPF1; LUCA.
DR   GeneTree; ENSGT00390000008751; -.
DR   HOGENOM; HOG000161224; -.
DR   HOVERGEN; HBG001989; -.
DR   InParanoid; P06280; -.
DR   KO; K01189; -.
DR   OMA; CNVDCQE; -.
DR   OrthoDB; EOG091G0BGV; -.
DR   PhylomeDB; P06280; -.
DR   TreeFam; TF312909; -.
DR   BioCyc; MetaCyc:HS02389-MONOMER; -.
DR   BRENDA; 3.2.1.22; 2681.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; P06280; -.
DR   EvolutionaryTrace; P06280; -.
DR   GeneWiki; Alpha-galactosidase; -.
DR   GenomeRNAi; 2717; -.
DR   PRO; PR:P06280; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000102393; -.
DR   CleanEx; HS_GLA; -.
DR   ExpressionAtlas; P06280; baseline and differential.
DR   Genevisible; P06280; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IMP:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IMP:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IMP:UniProtKB.
DR   GO; GO:0004557; F:alpha-galactosidase activity; IDA:UniProtKB.
DR   GO; GO:0003824; F:catalytic activity; IDA:UniProtKB.
DR   GO; GO:0016936; F:galactoside binding; IEA:Ensembl.
DR   GO; GO:0016787; F:hydrolase activity; TAS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0052692; F:raffinose alpha-galactosidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005102; F:receptor binding; IDA:UniProtKB.
DR   GO; GO:0016139; P:glycoside catabolic process; IBA:GO_Central.
DR   GO; GO:0046479; P:glycosphingolipid catabolic process; TAS:UniProtKB.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0046477; P:glycosylceramide catabolic process; ISS:UniProtKB.
DR   GO; GO:0045019; P:negative regulation of nitric oxide biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0051001; P:negative regulation of nitric-oxide synthase activity; ISS:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0009311; P:oligosaccharide metabolic process; IDA:UniProtKB.
DR   CDD; cd14792; GH27; 1.
DR   Gene3D; 3.20.20.70; -; 2.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR002241; Glyco_hydro_27.
DR   InterPro; IPR000111; Glyco_hydro_27/36_CS.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   Pfam; PF16499; Melibiase_2; 1.
DR   PRINTS; PR00740; GLHYDRLASE27.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   PROSITE; PS00512; ALPHA_GALACTOSIDASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Glycosidase;
KW   Hydrolase; Lysosome; Pharmaceutical; Reference proteome; RNA editing;
KW   Signal.
FT   SIGNAL        1     31
FT   CHAIN        32    429       Alpha-galactosidase A.
FT                                /FTId=PRO_0000001004.
FT   REGION      203    207       Substrate binding.
FT   ACT_SITE    170    170       Nucleophile. {ECO:0000250}.
FT   ACT_SITE    231    231       Proton donor. {ECO:0000250}.
FT   CARBOHYD    139    139       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:15003450}.
FT   CARBOHYD    192    192       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:15003450}.
FT   CARBOHYD    215    215       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:15003450,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    408    408       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     52     94
FT   DISULFID     56     63
FT   DISULFID    142    172
FT   DISULFID    202    223
FT   DISULFID    378    382
FT   VARIANT       3      3       L -> P (polymorphism; does not affect
FT                                enzyme activity; dbSNP:rs150547672).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077365.
FT   VARIANT       3      3       L -> V (polymorphism; does not affect
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077366.
FT   VARIANT      12     14       Missing (in FD; has 4% of wild-type
FT                                activity). {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062550.
FT   VARIANT      20     20       A -> D (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077367.
FT   VARIANT      20     20       A -> P (in FD; atypical; loss of enzyme
FT                                activity; dbSNP:rs104894847).
FT                                {ECO:0000269|PubMed:26415523,
FT                                ECO:0000269|PubMed:7596372,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012362.
FT   VARIANT      21     21       L -> P (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077368.
FT   VARIANT      31     31       A -> V (in FD).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012363.
FT   VARIANT      32     32       L -> P (in FD).
FT                                {ECO:0000269|PubMed:7599642}.
FT                                /FTId=VAR_000431.
FT   VARIANT      33     33       D -> G (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077369.
FT   VARIANT      34     34       N -> S (in FD; dbSNP:rs28935192).
FT                                {ECO:0000269|PubMed:7504405,
FT                                ECO:0000269|PubMed:7599642,
FT                                ECO:0000269|PubMed:8395937}.
FT                                /FTId=VAR_000432.
FT   VARIANT      35     35       G -> E (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077370.
FT   VARIANT      35     35       G -> R (in FD).
FT                                {ECO:0000269|PubMed:8069316}.
FT                                /FTId=VAR_000433.
FT   VARIANT      36     36       L -> W (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077371.
FT   VARIANT      40     40       P -> L (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012364.
FT   VARIANT      40     40       P -> S (in FD; loss of enzyme activity;
FT                                dbSNP:rs104894831).
FT                                {ECO:0000269|PubMed:2152885,
FT                                ECO:0000269|PubMed:26415523,
FT                                ECO:0000269|PubMed:9105656,
FT                                ECO:0000269|PubMed:9452111}.
FT                                /FTId=VAR_000434.
FT   VARIANT      42     42       M -> L (in FD; dbSNP:rs797044613).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062551.
FT   VARIANT      42     42       M -> T (in FD; loss of enzyme activity;
FT                                dbSNP:rs398123201).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077372.
FT   VARIANT      42     42       M -> V (in FD).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012365.
FT   VARIANT      43     43       G -> R (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062552.
FT   VARIANT      45     46       LH -> RS (in FD).
FT                                /FTId=VAR_012366.
FT   VARIANT      45     45       L -> P (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077373.
FT   VARIANT      46     46       H -> P (in FD; has 36% of wild-type
FT                                activity). {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062553.
FT   VARIANT      46     46       H -> R (in FD; dbSNP:rs398123203).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012367.
FT   VARIANT      46     46       H -> Y (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012368.
FT   VARIANT      47     47       W -> G (in FD; decreased alpha-
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:27211852}.
FT                                /FTId=VAR_012369.
FT   VARIANT      47     47       W -> R (in FD; decreased alpha-
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:27211852}.
FT                                /FTId=VAR_076478.
FT   VARIANT      48     48       E -> D (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077374.
FT   VARIANT      49     49       R -> L (in FD).
FT                                {ECO:0000269|PubMed:8069316}.
FT                                /FTId=VAR_000435.
FT   VARIANT      49     49       R -> P (in FD; dbSNP:rs398123205).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012370.
FT   VARIANT      49     49       R -> S (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012371.
FT   VARIANT      52     52       C -> R (in FD).
FT                                {ECO:0000269|PubMed:8807334,
FT                                ECO:0000269|PubMed:8931708}.
FT                                /FTId=VAR_000436.
FT   VARIANT      52     52       C -> S (in FD).
FT                                /FTId=VAR_000437.
FT   VARIANT      56     56       C -> F (in FD).
FT                                /FTId=VAR_000438.
FT   VARIANT      56     56       C -> G (in FD; dbSNP:rs28935193).
FT                                {ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000439.
FT   VARIANT      56     56       C -> Y (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523,
FT                                ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012372.
FT   VARIANT      59     59       E -> K (in FD).
FT                                /FTId=VAR_000440.
FT   VARIANT      60     60       P -> L (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077375.
FT   VARIANT      64     64       I -> F (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077376.
FT   VARIANT      65     65       S -> T (in FD; does not affect enzyme
FT                                function; dbSNP:rs104894848).
FT                                {ECO:0000269|PubMed:12786754,
FT                                ECO:0000269|PubMed:9554750}.
FT                                /FTId=VAR_032290.
FT   VARIANT      66     66       E -> Q (in FD; has 52% of wild-type
FT                                activity; dbSNP:rs28935191).
FT                                {ECO:0000269|PubMed:1315715,
FT                                ECO:0000269|PubMed:19621417,
FT                                ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000441.
FT   VARIANT      71     71       E -> G (polymorphism; does not affect
FT                                enzyme activity; dbSNP:rs781927744).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077377.
FT   VARIANT      72     72       M -> V (in FD; atypical).
FT                                {ECO:0000269|PubMed:9105656,
FT                                ECO:0000269|PubMed:9452090}.
FT                                /FTId=VAR_000442.
FT   VARIANT      80     80       G -> D (in FD; unknown pathological
FT                                significance; decreased enzyme activity;
FT                                dbSNP:rs781838005).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077378.
FT   VARIANT      85     85       G -> D (in FD).
FT                                {ECO:0000269|PubMed:7599642}.
FT                                /FTId=VAR_000443.
FT   VARIANT      86     86       Y -> C (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012373.
FT   VARIANT      86     86       Y -> H (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077379.
FT   VARIANT      89     89       L -> P (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012374.
FT   VARIANT      89     89       L -> R (in FD).
FT                                /FTId=VAR_000444.
FT   VARIANT      91     91       I -> N (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077380.
FT   VARIANT      91     91       I -> T (in FD; mild; loss of enzyme
FT                                activity). {ECO:0000269|PubMed:26415523,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012375.
FT   VARIANT      92     92       D -> H (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012376.
FT   VARIANT      92     92       D -> Y (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012377.
FT   VARIANT      93     93       D -> G (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012378.
FT   VARIANT      93     93       D -> N (in FD; has no enzyme activity).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062554.
FT   VARIANT      94     94       C -> S (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_012379.
FT   VARIANT      94     94       C -> Y (in FD; loss of enzyme activity;
FT                                dbSNP:rs113173389).
FT                                {ECO:0000269|PubMed:26415523,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012380.
FT   VARIANT      95     95       W -> S (in FD).
FT                                {ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012381.
FT   VARIANT      97     97       A -> V (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012382.
FT   VARIANT     100    100       R -> K (in FD).
FT                                /FTId=VAR_000445.
FT   VARIANT     100    100       R -> T (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012383.
FT   VARIANT     112    117       Missing (in FD).
FT                                /FTId=VAR_000446.
FT   VARIANT     112    112       R -> C (in FD; dbSNP:rs104894834).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:1315715,
FT                                ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000447.
FT   VARIANT     112    112       R -> H (in FD; mild; dbSNP:rs372966991).
FT                                {ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_000448.
FT   VARIANT     112    112       R -> S (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062555.
FT   VARIANT     113    113       F -> I (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077381.
FT   VARIANT     113    113       F -> L (in FD; mild).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012384.
FT   VARIANT     113    113       F -> S (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012385.
FT   VARIANT     120    121       LA -> PT (in FD).
FT                                /FTId=VAR_000449.
FT   VARIANT     120    120       L -> V (in FD; has 42% of wild-type
FT                                activity). {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062556.
FT   VARIANT     121    121       A -> T (in FD; unknown pathological
FT                                significance; decreased enzyme activity;
FT                                dbSNP:rs782197638).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077382.
FT   VARIANT     128    128       G -> E (in FD).
FT                                {ECO:0000269|PubMed:8807334}.
FT                                /FTId=VAR_000450.
FT   VARIANT     131    131       L -> P (in FD).
FT                                /FTId=VAR_000451.
FT   VARIANT     134    134       Y -> S (in FD).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012386.
FT   VARIANT     135    135       A -> V (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062557.
FT   VARIANT     138    138       G -> R (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012387.
FT   VARIANT     142    142       C -> R (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012388.
FT   VARIANT     142    142       C -> Y (in FD).
FT                                {ECO:0000269|PubMed:7759078,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000452.
FT   VARIANT     143    143       A -> P (in FD; dbSNP:rs104894845).
FT                                {ECO:0000269|PubMed:11889412}.
FT                                /FTId=VAR_000453.
FT   VARIANT     143    143       A -> T (in FD; unknown pathological
FT                                significance; dbSNP:rs104894845).
FT                                {ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:16533976,
FT                                ECO:0000269|PubMed:27142856,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012389.
FT   VARIANT     144    144       G -> V (in FD).
FT                                /FTId=VAR_000454.
FT   VARIANT     146    146       P -> S (in FD; mild; dbSNP:rs28935194).
FT                                /FTId=VAR_000455.
FT   VARIANT     148    148       S -> N (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012390.
FT   VARIANT     148    148       S -> R (in FD).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012391.
FT   VARIANT     154    154       I -> T (polymorphism; does not affect
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077383.
FT   VARIANT     156    156       A -> T (in FD; dbSNP:rs28935195).
FT                                {ECO:0000269|PubMed:7599642}.
FT                                /FTId=VAR_000456.
FT   VARIANT     156    156       A -> V (in FD).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:7759078,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000457.
FT   VARIANT     162    162       W -> C (in FD).
FT                                {ECO:0000269|PubMed:8931708}.
FT                                /FTId=VAR_012392.
FT   VARIANT     162    162       W -> R (in FD; dbSNP:rs28935196).
FT                                {ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000458.
FT   VARIANT     163    163       G -> V (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012393.
FT   VARIANT     164    164       V -> G (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077384.
FT   VARIANT     164    164       V -> L (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077385.
FT   VARIANT     165    165       D -> V (in FD).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:8069316}.
FT                                /FTId=VAR_000459.
FT   VARIANT     166    166       L -> V (in FD).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:7759078,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000460.
FT   VARIANT     167    167       L -> Q (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077386.
FT   VARIANT     170    170       D -> V (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012394.
FT   VARIANT     171    171       G -> D (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062558.
FT   VARIANT     172    172       C -> R (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012395.
FT   VARIANT     172    172       C -> Y (in FD).
FT                                /FTId=VAR_000461.
FT   VARIANT     180    180       L -> F (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077387.
FT   VARIANT     183    183       G -> D (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012396.
FT   VARIANT     187    187       M -> I (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077388.
FT   VARIANT     187    187       M -> V (in FD; decreased enzyme
FT                                activity). {ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_012397.
FT   VARIANT     196    196       R -> S (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077389.
FT   VARIANT     198    198       I -> T (in FD; unknown pathological
FT                                significance; decreased enzyme activity;
FT                                dbSNP:rs727503950).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077390.
FT   VARIANT     201    201       S -> F (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062559.
FT   VARIANT     202    202       C -> W (in FD; dbSNP:rs28936082).
FT                                {ECO:0000269|PubMed:10208848}.
FT                                /FTId=VAR_000462.
FT   VARIANT     202    202       C -> Y (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012398.
FT   VARIANT     204    204       W -> R (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077391.
FT   VARIANT     205    207       Missing (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012399.
FT   VARIANT     205    205       P -> T (in FD; dbSNP:rs397515870).
FT                                {ECO:0000269|PubMed:8807334,
FT                                ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_000463.
FT   VARIANT     213    213       K -> R (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077392.
FT   VARIANT     214    214       P -> L (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077393.
FT   VARIANT     215    215       N -> S (in FD; mild; dbSNP:rs28935197).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:8395937,
FT                                ECO:0000269|PubMed:9452111}.
FT                                /FTId=VAR_000464.
FT   VARIANT     216    216       Y -> D (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012400.
FT   VARIANT     219    219       I -> M (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077394.
FT   VARIANT     219    219       I -> N (in FD).
FT                                /FTId=VAR_000465.
FT   VARIANT     219    219       I -> T (in FD; has 46% of wild-type
FT                                activity). {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062560.
FT   VARIANT     223    223       C -> G (in FD).
FT                                {ECO:0000269|PubMed:10208848}.
FT                                /FTId=VAR_012401.
FT   VARIANT     224    224       N -> D (in FD).
FT                                {ECO:0000269|PubMed:10208848,
FT                                ECO:0000269|PubMed:9452111}.
FT                                /FTId=VAR_000466.
FT   VARIANT     224    224       N -> S (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012402.
FT   VARIANT     226    226       W -> R (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012403.
FT   VARIANT     227    227       R -> P (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077395.
FT   VARIANT     227    227       R -> Q (in FD; dbSNP:rs28935198).
FT                                {ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000467.
FT   VARIANT     228    228       N -> S (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077396.
FT   VARIANT     230    230       A -> T (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_012404.
FT   VARIANT     231    231       D -> N (in FD).
FT                                {ECO:0000269|PubMed:8863162}.
FT                                /FTId=VAR_000468.
FT   VARIANT     234    234       D -> E (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062561.
FT   VARIANT     235    235       S -> C (in FD; dbSNP:rs797044746).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012405.
FT   VARIANT     236    236       W -> C (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012406.
FT   VARIANT     236    236       W -> L (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012407.
FT   VARIANT     242    242       I -> N (in FD).
FT                                {ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012408.
FT   VARIANT     242    242       I -> V (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077397.
FT   VARIANT     243    243       L -> F (in FD; unknown pathological
FT                                significance; decreased enzyme activity;
FT                                dbSNP:rs397515874).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077398.
FT   VARIANT     244    244       D -> H (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012409.
FT   VARIANT     244    244       D -> N (in FD; dbSNP:rs727503948).
FT                                /FTId=VAR_000469.
FT   VARIANT     247    247       S -> P (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077399.
FT   VARIANT     247    247       S -> SWTS (in FD).
FT                                /FTId=VAR_000470.
FT   VARIANT     249    249       N -> K (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077400.
FT   VARIANT     253    253       I -> T (in FD; unknown pathological
FT                                significance; decreased enzyme activity;
FT                                dbSNP:rs727505292).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077401.
FT   VARIANT     254    254       V -> A (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077402.
FT   VARIANT     258    258       G -> R (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012410.
FT   VARIANT     259    259       P -> L (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012411.
FT   VARIANT     259    259       P -> R (in FD; decreased enzyme
FT                                activity). {ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_012412.
FT   VARIANT     260    260       G -> A (in FD).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012413.
FT   VARIANT     261    261       G -> D (in FD).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012414.
FT   VARIANT     262    262       W -> R (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077403.
FT   VARIANT     263    263       N -> S (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012415.
FT   VARIANT     264    264       D -> V (in FD; dbSNP:rs28935486).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000471.
FT   VARIANT     264    264       D -> Y (in FD; dbSNP:rs190347120).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062562.
FT   VARIANT     265    265       P -> R (in FD).
FT                                {ECO:0000269|PubMed:8931708}.
FT                                /FTId=VAR_012416.
FT   VARIANT     266    266       D -> H (in FD).
FT                                {ECO:0000269|PubMed:10916280}.
FT                                /FTId=VAR_032291.
FT   VARIANT     266    266       D -> N (in FD).
FT                                {ECO:0000269|PubMed:11076046}.
FT                                /FTId=VAR_012418.
FT   VARIANT     266    266       D -> V (in FD; dbSNP:rs28935487).
FT                                {ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000472.
FT   VARIANT     267    267       M -> I (in FD; dbSNP:rs730880451).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012419.
FT   VARIANT     269    269       V -> A (in FD; dbSNP:rs28935488).
FT                                {ECO:0000269|PubMed:8395937}.
FT                                /FTId=VAR_000473.
FT   VARIANT     269    269       V -> G (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077404.
FT   VARIANT     272    272       N -> K (in FD).
FT                                /FTId=VAR_000474.
FT   VARIANT     272    272       N -> S (in FD; dbSNP:rs28935495).
FT                                {ECO:0000269|PubMed:15162124}.
FT                                /FTId=VAR_032292.
FT   VARIANT     276    276       S -> G (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_062563.
FT   VARIANT     279    279       Q -> E (in FD; mild; does not
FT                                significantly affect the enzyme activity
FT                                but the mutant protein levels are
FT                                decreased presumably in the ER of the
FT                                cells; dbSNP:rs28935485).
FT                                {ECO:0000269|PubMed:10838196,
FT                                ECO:0000269|PubMed:1315715,
FT                                ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000475.
FT   VARIANT     279    279       Q -> H (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012420.
FT   VARIANT     280    280       Q -> H (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012421.
FT   VARIANT     284    284       M -> T (in FD).
FT                                {ECO:0000269|PubMed:8807334}.
FT                                /FTId=VAR_000476.
FT   VARIANT     285    285       A -> P (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062564.
FT   VARIANT     287    287       W -> C (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012422.
FT   VARIANT     287    287       W -> G (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012423.
FT   VARIANT     288    288       A -> D (in FD).
FT                                /FTId=VAR_000477.
FT   VARIANT     289    289       I -> F (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012424.
FT   VARIANT     289    289       I -> V (polymorphism; decreased enzyme
FT                                activity; dbSNP:rs140329381).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077405.
FT   VARIANT     296    296       M -> I (in FD; atypical;
FT                                dbSNP:rs104894846).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:7596372,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012425.
FT   VARIANT     296    296       M -> V (in FD; mild; dbSNP:rs104894830).
FT                                {ECO:0000269|PubMed:1846223}.
FT                                /FTId=VAR_000478.
FT   VARIANT     297    297       S -> F (in FD; dbSNP:rs28935489).
FT                                {ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000479.
FT   VARIANT     298    298       N -> H (in FD).
FT                                {ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012426.
FT   VARIANT     298    298       N -> K (in FD).
FT                                {ECO:0000269|PubMed:8807334}.
FT                                /FTId=VAR_000480.
FT   VARIANT     298    298       N -> S (in FD).
FT                                {ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_012427.
FT   VARIANT     300    300       L -> F (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062565.
FT   VARIANT     301    301       R -> Q (in FD; mild; does not
FT                                significantly affect the enzyme activity
FT                                but the mutant protein levels are
FT                                decreased presumably in the ER of the
FT                                cells; dbSNP:rs104894828).
FT                                {ECO:0000269|PubMed:10208848,
FT                                ECO:0000269|PubMed:10838196,
FT                                ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:1315715,
FT                                ECO:0000269|PubMed:2171331,
FT                                ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:7599642,
FT                                ECO:0000269|PubMed:8738659,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000481.
FT   VARIANT     309    309       A -> V (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077406.
FT   VARIANT     313    313       D -> N (polymorphism; does not affect
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077407.
FT   VARIANT     313    313       D -> Y (in FD; dbSNP:rs28935490).
FT                                {ECO:0000269|PubMed:11668641,
FT                                ECO:0000269|PubMed:7504405,
FT                                ECO:0000269|PubMed:9452111}.
FT                                /FTId=VAR_000482.
FT   VARIANT     315    315       D -> N (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077408.
FT   VARIANT     316    322       Missing (in FD).
FT                                {ECO:0000269|PubMed:8931708}.
FT                                /FTId=VAR_012429.
FT   VARIANT     316    316       V -> A (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077409.
FT   VARIANT     316    316       V -> E (in FD).
FT                                {ECO:0000269|PubMed:8069316}.
FT                                /FTId=VAR_000483.
FT   VARIANT     317    317       I -> S (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077410.
FT   VARIANT     320    320       N -> K (in FD).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012430.
FT   VARIANT     320    320       N -> Y (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:10916280,
FT                                ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_012431.
FT   VARIANT     321    321       Q -> E (in FD; dbSNP:rs730880439).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012432.
FT   VARIANT     323    323       P -> R (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077411.
FT   VARIANT     327    327       Q -> K (in FD; dbSNP:rs28935491).
FT                                {ECO:0000269|PubMed:10208848,
FT                                ECO:0000269|PubMed:8395937}.
FT                                /FTId=VAR_000484.
FT   VARIANT     327    327       Q -> L (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077412.
FT   VARIANT     327    327       Q -> R (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077413.
FT   VARIANT     328    328       G -> A (in FD; dbSNP:rs28935492).
FT                                {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:7504405}.
FT                                /FTId=VAR_000486.
FT   VARIANT     328    328       G -> R (in FD; loss of enzyme activity;
FT                                dbSNP:rs104894832).
FT                                {ECO:0000269|PubMed:1315715,
FT                                ECO:0000269|PubMed:26415523,
FT                                ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000485.
FT   VARIANT     328    328       G -> V (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062566.
FT   VARIANT     330    330       Q -> R (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077414.
FT   VARIANT     338    338       E -> K (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062567.
FT   VARIANT     340    340       W -> R (in FD).
FT                                {ECO:0000269|PubMed:8875188}.
FT                                /FTId=VAR_012433.
FT   VARIANT     341    341       E -> K (in FD).
FT                                {ECO:0000269|PubMed:10090526}.
FT                                /FTId=VAR_012434.
FT   VARIANT     342    342       R -> P (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077415.
FT   VARIANT     342    342       R -> Q (in FD; severe; dbSNP:rs28935493).
FT                                /FTId=VAR_000487.
FT   VARIANT     352    352       A -> G (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077416.
FT   VARIANT     356    356       R -> P (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077417.
FT   VARIANT     356    356       R -> Q (in FD; has 15% of wild-type
FT                                activity). {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062568.
FT   VARIANT     356    356       R -> W (in FD; severe;
FT                                dbSNP:rs104894827).
FT                                {ECO:0000269|PubMed:2539398}.
FT                                /FTId=VAR_000488.
FT   VARIANT     358    358       E -> A (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062569.
FT   VARIANT     358    358       E -> K (in FD; loss of enzyme activity;
FT                                dbSNP:rs797044774).
FT                                {ECO:0000269|PubMed:26415523,
FT                                ECO:0000269|PubMed:9452068}.
FT                                /FTId=VAR_000489.
FT   VARIANT     358    358       Missing (in FD).
FT                                {ECO:0000269|PubMed:10666480,
FT                                ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:8807334,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_000490.
FT   VARIANT     360    360       G -> C (in FD; has 6% of wild-type
FT                                activity; dbSNP:rs782598150).
FT                                {ECO:0000269|PubMed:19621417}.
FT                                /FTId=VAR_062570.
FT   VARIANT     360    360       G -> S (in FD; loss of enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077418.
FT   VARIANT     361    361       G -> R (in FD; severe; dbSNP:rs28935494).
FT                                {ECO:0000269|PubMed:8395937}.
FT                                /FTId=VAR_000491.
FT   VARIANT     363    363       R -> H (in FD; dbSNP:rs111422676).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012435.
FT   VARIANT     373    373       G -> D (in FD).
FT                                {ECO:0000269|PubMed:11295840}.
FT                                /FTId=VAR_012436.
FT   VARIANT     373    373       G -> S (in FD; dbSNP:rs727504348).
FT                                {ECO:0000269|PubMed:7575533,
FT                                ECO:0000269|PubMed:9105656}.
FT                                /FTId=VAR_012437.
FT   VARIANT     375    375       G -> A (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077419.
FT   VARIANT     377    377       A -> D (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012438.
FT   VARIANT     378    378       C -> Y (in FD).
FT                                {ECO:0000269|PubMed:10666480}.
FT                                /FTId=VAR_012439.
FT   VARIANT     383    383       Missing (in FD; severe; with facial
FT                                telangiectasias).
FT                                {ECO:0000269|PubMed:8834244}.
FT                                /FTId=VAR_000492.
FT   VARIANT     392    392       R -> S (in FD; unknown pathological
FT                                significance; decreased enzyme activity).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077420.
FT   VARIANT     396    396       F -> Y (in RNA edited version).
FT                                /FTId=VAR_000493.
FT   VARIANT     399    399       W -> S (in FD; unknown pathological
FT                                significance; decreased enzyme activity;
FT                                dbSNP:rs782449839).
FT                                {ECO:0000269|PubMed:26415523}.
FT                                /FTId=VAR_077421.
FT   VARIANT     404    404       Missing (in FD; mild; loss of enzyme
FT                                activity). {ECO:0000269|PubMed:15712228,
FT                                ECO:0000269|PubMed:26415523,
FT                                ECO:0000269|PubMed:7504405,
FT                                ECO:0000269|PubMed:9100224}.
FT                                /FTId=VAR_000494.
FT   VARIANT     409    409       P -> A (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012440.
FT   VARIANT     409    409       P -> T (in FD).
FT                                {ECO:0000269|PubMed:11668641}.
FT                                /FTId=VAR_012441.
FT   VARIANT     410    410       T -> A (in FD; mild; dbSNP:rs104894852).
FT                                {ECO:0000269|PubMed:12694230}.
FT                                /FTId=VAR_032293.
FT   VARIANT     414    414       L -> S (in FD).
FT                                {ECO:0000269|PubMed:15712228}.
FT                                /FTId=VAR_062571.
FT   STRAND       42     46       {ECO:0000244|PDB:3HG3}.
FT   HELIX        47     50       {ECO:0000244|PDB:3HG3}.
FT   TURN         56     58       {ECO:0000244|PDB:3HG3}.
FT   TURN         60     62       {ECO:0000244|PDB:3HG3}.
FT   STRAND       63     65       {ECO:0000244|PDB:3HG3}.
FT   HELIX        66     78       {ECO:0000244|PDB:3HG3}.
FT   HELIX        81     84       {ECO:0000244|PDB:3HG3}.
FT   STRAND       88     90       {ECO:0000244|PDB:3HG3}.
FT   STRAND      102    104       {ECO:0000244|PDB:3GXT}.
FT   TURN        110    112       {ECO:0000244|PDB:3HG3}.
FT   STRAND      113    115       {ECO:0000244|PDB:1R47}.
FT   HELIX       116    126       {ECO:0000244|PDB:3HG3}.
FT   STRAND      130    140       {ECO:0000244|PDB:3HG3}.
FT   STRAND      144    146       {ECO:0000244|PDB:3HG3}.
FT   TURN        149    151       {ECO:0000244|PDB:3GXN}.
FT   HELIX       152    162       {ECO:0000244|PDB:3HG3}.
FT   STRAND      166    170       {ECO:0000244|PDB:3HG3}.
FT   HELIX       177    193       {ECO:0000244|PDB:3HG3}.
FT   STRAND      199    202       {ECO:0000244|PDB:3HG3}.
FT   HELIX       205    208       {ECO:0000244|PDB:3HG3}.
FT   TURN        209    211       {ECO:0000244|PDB:3HG3}.
FT   HELIX       216    222       {ECO:0000244|PDB:3HG3}.
FT   STRAND      224    227       {ECO:0000244|PDB:3HG3}.
FT   HELIX       236    248       {ECO:0000244|PDB:3HG3}.
FT   HELIX       250    253       {ECO:0000244|PDB:3HG3}.
FT   TURN        254    256       {ECO:0000244|PDB:3HG3}.
FT   STRAND      261    264       {ECO:0000244|PDB:3HG3}.
FT   STRAND      272    274       {ECO:0000244|PDB:3HG3}.
FT   HELIX       277    289       {ECO:0000244|PDB:3HG3}.
FT   STRAND      294    296       {ECO:0000244|PDB:3HG3}.
FT   HELIX       305    311       {ECO:0000244|PDB:3HG3}.
FT   HELIX       314    320       {ECO:0000244|PDB:3HG3}.
FT   STRAND      329    334       {ECO:0000244|PDB:3HG3}.
FT   STRAND      337    343       {ECO:0000244|PDB:3HG3}.
FT   HELIX       345    347       {ECO:0000244|PDB:3S5Z}.
FT   STRAND      349    355       {ECO:0000244|PDB:3HG3}.
FT   STRAND      359    361       {ECO:0000244|PDB:3HG3}.
FT   STRAND      363    368       {ECO:0000244|PDB:3HG3}.
FT   HELIX       369    371       {ECO:0000244|PDB:3HG3}.
FT   HELIX       373    375       {ECO:0000244|PDB:3HG3}.
FT   TURN        376    378       {ECO:0000244|PDB:3HG3}.
FT   STRAND      379    390       {ECO:0000244|PDB:3HG3}.
FT   STRAND      392    398       {ECO:0000244|PDB:3HG3}.
FT   STRAND      402    407       {ECO:0000244|PDB:3HG3}.
FT   STRAND      412    419       {ECO:0000244|PDB:3HG3}.
FT   HELIX       420    424       {ECO:0000244|PDB:3HG3}.
SQ   SEQUENCE   429 AA;  48767 MW;  613F8BF21B107D7B CRC64;
     MQLRNPELHL GCALALRFLA LVSWDIPGAR ALDNGLARTP TMGWLHWERF MCNLDCQEEP
     DSCISEKLFM EMAELMVSEG WKDAGYEYLC IDDCWMAPQR DSEGRLQADP QRFPHGIRQL
     ANYVHSKGLK LGIYADVGNK TCAGFPGSFG YYDIDAQTFA DWGVDLLKFD GCYCDSLENL
     ADGYKHMSLA LNRTGRSIVY SCEWPLYMWP FQKPNYTEIR QYCNHWRNFA DIDDSWKSIK
     SILDWTSFNQ ERIVDVAGPG GWNDPDMLVI GNFGLSWNQQ VTQMALWAIM AAPLFMSNDL
     RHISPQAKAL LQDKDVIAIN QDPLGKQGYQ LRQGDNFEVW ERPLSGLAWA VAMINRQEIG
     GPRSYTIAVA SLGKGVACNP ACFITQLLPV KRKLGFYEWT SRLRSHINPT GTVLLQLENT
     MQMSLKDLL
//
